ABNX.PA
ABIONYX Pharma SA [ABNX.PA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ABNX.PA Stock Summary
Top 10 Correlated ETFs
ABNX.PA
Top 10 Correlated Stocks
ABNX.PA
In the News
ABNX.PA Financial details
Company Rating
Sell
Market Cap
36.04M
Income
-6.28M
Revenue
8.29M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
63
Optionable
No
Shortable
Yes
Earnings
25 Apr 2024
P/E
-8.41
Forward P/E
-
PEG
-1.89
P/S
7.93
P/B
5.05
P/C
-
P/FCF
-11.78
Quick Ratio
0.79
Current Ratio
1.49
Debt / Equity
-
LT Debt / Equity
0.61
-
-
EPS (TTM)
-0.22
EPS next Y
-
EPS next Q
-
EPS this Y
-26.67%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
16.17%
EPS Q/Q
-50.32%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-27%
ROE
-48%
ROC
-0.38%
Gross Margin
12%
Oper. Margin
-78%
Profit Margin
-82%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.91-2.16
52W High
-
52W Low
-
RSI
53
Rel Volume
0.93
Avg Volume
52.93K
Volume
48.97K
Perf Week
-2.36%
Perf Month
0.37%
Perf Quarter
-16.09%
Perf Half Y
-18.64%
-
-
-
-
Beta
-0.123
-
-
Volatility
0.02%, 0.07%
Prev Close
0.37%
Price
1.074
Change
-0.56%
ABNX.PA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0.03 | 0.19 | 0.14 | |
| Net income per share | 0.09 | -0.08 | -0.23 | -0.15 | -0.11 | |
| Operating cash flow per share | -0.19 | -0.03 | -0.27 | -0.12 | 0 | |
| Free cash flow per share | -0.19 | -0.03 | -0.28 | -0.13 | 0 | |
| Cash per share | 0.4 | 0.41 | 0.32 | 0.14 | 0 | |
| Book value per share | 0.32 | 0.29 | 0.43 | 0.26 | 0 | |
| Tangible book value per share | 0.32 | 0.29 | 0.21 | 0.06 | 0 | |
| Share holders equity per share | 0.32 | 0.29 | 0.43 | 0.26 | 0 | |
| Interest debt per share | 0.07 | 0.01 | 0.2 | 0.15 | 0 | |
| Market cap | 6.94M | 22.26M | 60.83M | 48.16M | 41.05M | |
| Enterprise value | -206.11K | 13.13M | 57.85M | 48.13M | 0 | |
| P/E ratio | 3.75 | -11.8 | -10.43 | -11.19 | -11.73 | |
| Price to sales ratio | 0 | 0 | 90.12 | 9.17 | 8.92 | |
| POCF ratio | -1.76 | -37.16 | -9.09 | -14.34 | 0 | |
| PFCF ratio | -1.76 | -29.8 | -8.87 | -13.63 | 0 | |
| P/B Ratio | 1.04 | 3.36 | 5.7 | 6.72 | 0 | |
| PTB ratio | 1.04 | 3.36 | 5.7 | 6.72 | 0 | |
| EV to sales | 0 | 0 | 85.71 | 9.16 | 0 | |
| Enterprise value over EBITDA | -0.09 | -7.04 | -10.16 | -12 | 0 | |
| EV to operating cash flow | 0.05 | -21.92 | -8.65 | -14.33 | 0 | |
| EV to free cash flow | 0.05 | -17.58 | -8.44 | -13.62 | 0 | |
| Earnings yield | 0.27 | -0.08 | -0.1 | -0.09 | -0.09 | |
| Free cash flow yield | -0.57 | -0.03 | -0.11 | -0.07 | 0 | |
| Debt to equity | 0.18 | 0 | 0.46 | 0.56 | 0 | |
| Debt to assets | 0.12 | 0 | 0.23 | 0.25 | 0 | |
| Net debt to EBITDA | -3.18 | 4.9 | 0.52 | 0.01 | 0 | |
| Current ratio | 2.92 | 2.79 | 1.93 | 1.49 | 0 | |
| Interest coverage | 6.39 | -31.24 | -744 | -67.36 | -11.67 | |
| Income quality | -2.14 | 0.32 | 1.15 | 0.8 | 0 | |
| Dividend Yield | 0 | 0.07 | 0.07 | 0 | 0 | |
| Payout ratio | 0 | -0.82 | -0.68 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0.87 | 0.25 | 0 | |
| Research and developement to revenue | 0 | 0 | 7.3 | 0.21 | 0.33 | |
| Intangibles to total assets | 0 | 0 | 0.25 | 0.34 | 0 | |
| Capex to operating cash flow | 0 | 0.25 | 0.02 | 0.05 | 0 | |
| Capex to revenue | 0 | 0 | -0.25 | -0.03 | 0 | |
| Capex to depreciation | 0 | -6.73 | -1.39 | -1.3 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 1.21 | 0.1 | 0 | |
| Graham number | 0.81 | 0.75 | 1.5 | 0.94 | 0 | |
| ROIC | 0.28 | -0.3 | -0.33 | -0.32 | 0 | |
| Return on tangible assets | 0.18 | -0.18 | -0.36 | -0.41 | 0 | |
| Graham Net | 0.29 | 0.27 | 0.01 | -0.08 | 0 | |
| Working capital | 6.66M | 6.43M | 6.26M | 2.48M | 0 | |
| Tangible asset value | 6.67M | 6.58M | 5.22M | 1.72M | 0 | |
| Net current asset value | 6.54M | 6.37M | 1.86M | -1.08M | 0 | |
| Invested capital | 0.18 | 0 | 0.46 | 0.56 | 0 | |
| Average receivables | 885K | 1.31M | 2.73M | 3.84M | 0 | |
| Average payables | 1.69M | 1.83M | 2.56M | 2.28M | 0 | |
| Average inventory | 0 | 19K | 107.5K | 162K | 0 | |
| Days sales outstanding | 0 | 0 | 2.5K | 212.18 | 0 | |
| Days payables outstanding | 6.37K | 11K | 2.37K | 146.52 | 0 | |
| Days of inventory on hand | 0 | 173.38 | 155.3 | 11.62 | 0 | |
| Receivables turnover | 0 | 0 | 0.15 | 1.72 | 0 | |
| Payables turnover | 0.06 | 0.03 | 0.15 | 2.49 | 0 | |
| Inventory turnover | 0 | 2.11 | 2.35 | 31.4 | 0 | |
| ROE | 0.28 | -0.28 | -0.55 | -0.6 | 0 | |
| Capex per share | 0 | -0.01 | -0.01 | -0.01 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0.09 | 0.04 | 0.07 | 0.08 | |
| Net income per share | 0 | -0.06 | -0.04 | -0.08 | -0.04 | |
| Operating cash flow per share | 0 | 0.01 | -0.04 | -0.09 | 0 | |
| Free cash flow per share | 0 | 0.01 | -0.05 | -0.09 | 0 | |
| Cash per share | 0 | 0.14 | 0.07 | 0.07 | 0 | |
| Book value per share | 0 | 0.26 | 0.17 | 0.17 | 0 | |
| Tangible book value per share | 0 | 0.06 | -0.02 | -0.02 | 0 | |
| Share holders equity per share | 0 | 0.26 | 0.17 | 0.17 | 0 | |
| Interest debt per share | 0 | 0.15 | 0.05 | 0.15 | 0 | |
| Market cap | 0 | 48.38M | 64.78M | 35.23M | 41.05M | |
| Enterprise value | 4.03M | 48.35M | 62.85M | 37.56M | 0 | |
| P/E ratio | 0 | -7.3 | -14.41 | -3.92 | -8.2 | |
| Price to sales ratio | 0 | 18.45 | 60.89 | 16.56 | 16.6 | |
| POCF ratio | 0 | 226.1 | -51.03 | -13.88 | 0 | |
| PFCF ratio | 0 | 308.18 | -49.7 | -13.5 | 0 | |
| P/B Ratio | 0 | 6.75 | 13.52 | 7.35 | 0 | |
| PTB ratio | 0 | 6.75 | 13.52 | 7.35 | 0 | |
| EV to sales | 3.02 | 18.44 | 59.07 | 17.65 | 0 | |
| Enterprise value over EBITDA | -5.11 | -23.25 | -58.38 | -14.07 | 0 | |
| EV to operating cash flow | 46.57 | 225.94 | -49.51 | -14.79 | 0 | |
| EV to free cash flow | 27.68 | 307.97 | -48.21 | -14.39 | 0 | |
| Earnings yield | 0 | -0.03 | -0.02 | -0.06 | -0.03 | |
| Free cash flow yield | 0 | 0 | -0.02 | -0.07 | 0 | |
| Debt to equity | 0 | 0.56 | 0.28 | 0.89 | 0 | |
| Debt to assets | 0 | 0.25 | 0.1 | 0.31 | 0 | |
| Net debt to EBITDA | -5.11 | 0.02 | 1.8 | -0.87 | 0 | |
| Current ratio | 0 | 1.49 | 1.01 | 1.01 | 0 | |
| Interest coverage | 0 | -22.9 | 0 | -36.55 | -5.75 | |
| Income quality | -0.1 | -0.13 | 1.13 | 1.13 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | -0.05 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.15 | 0.44 | 0.36 | 0.68 | 0.3 | |
| Intangibles to total assets | 0 | 0.34 | 0.39 | 0.39 | 0 | |
| Capex to operating cash flow | 0.68 | -0.27 | 0.03 | 0.03 | 0 | |
| Capex to revenue | 0.04 | -0.02 | -0.03 | -0.03 | 0 | |
| Capex to depreciation | -1.24 | -0.18 | -0.91 | -0.28 | 0 | |
| Stock based compensation to revenue | -0.14 | -0.07 | -0.06 | -0.03 | 0 | |
| Graham number | 0 | 0.58 | 0.39 | 0.55 | 0 | |
| ROIC | -0.1 | -0.13 | -0.18 | -0.2 | 0 | |
| Return on tangible assets | 0 | -0.16 | -0.13 | -0.27 | 0 | |
| Graham Net | 0 | -0.08 | -0.22 | -0.16 | 0 | |
| Working capital | 4.03M | 2.48M | 36K | 36K | 0 | |
| Tangible asset value | 0 | 1.72M | -656K | -656K | 0 | |
| Net current asset value | 4.03M | -1.08M | -3.28M | -3.28M | 0 | |
| Invested capital | 0 | 0.56 | 0.28 | 0.89 | 0 | |
| Average receivables | 2.57M | 1.53M | 2.01M | 2.2M | 0 | |
| Average payables | 1.02M | 926.5K | 1.89M | 1.92M | 0 | |
| Average inventory | 68.5K | 73.5K | 153K | 159K | 0 | |
| Days sales outstanding | 0 | 104.79 | 81.63 | 145.19 | 0 | |
| Days payables outstanding | 0 | 76.71 | 161.32 | 79.95 | 0 | |
| Days of inventory on hand | 0 | 6.09 | 13.38 | 6.63 | 0 | |
| Receivables turnover | 0 | 0.86 | 1.1 | 0.62 | 0 | |
| Payables turnover | 0 | 1.17 | 0.56 | 1.13 | 0 | |
| Inventory turnover | 0 | 14.79 | 6.73 | 13.57 | 0 | |
| ROE | -0.1 | -0.23 | -0.23 | -0.47 | 0 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
ABNX.PA Frequently Asked Questions
What is ABIONYX Pharma SA stock symbol ?
ABIONYX Pharma SA is a FR stock and trading under the symbol ABNX.PA
What is ABIONYX Pharma SA stock quote today ?
ABIONYX Pharma SA stock price is $1.074 today.
Is ABIONYX Pharma SA stock public?
Yes, ABIONYX Pharma SA is a publicly traded company.
Company Profile
- Volume Average 52.93K
- Market Capitalization 36.04M
- Employee 63
- CEO Sir Cyrille Tupin CPA
- Headquarters Balma,FR
- IPO Date 2015-03-30
-
Website
https://abionyx.com 
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. The company is developing CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. It has a strategic partnership with GTP Biologics and VBI Therapeutics Group for the bioproduction of the bio-HDL in France. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Balma, France.
